Heart Failure Clinical Trials Near You

Heart failure clinical trials in 2026 reflect the field's transformation from symptom management to disease modification. The four-pillar drug regimen — ACE inhibitor/ARB/ARNI (sacubitril/valsartan), beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor — is now standard for HFrEF, and trials are testing how quickly and aggressively to initiate all four medications simultaneously.

For HFpEF (preserved ejection fraction), which affects roughly half of heart failure patients but historically had no approved treatments, SGLT2 inhibitors (empagliflozin, dapagliflozin) demonstrated clear mortality and hospitalization benefits. Trials are now testing tirzepatide and semaglutide (GLP-1/GIP agonists) in obese HFpEF patients, addressing the metabolic and inflammatory pathways driving this phenotype.

Cardiac gene therapy trials are testing direct myocardial injection of genes encoding SERCA2a (a calcium pump critical for heart muscle contraction) and adenylyl cyclase 6 to restore contractile function at the molecular level. Cardiac cell therapy using allogeneic mesenchymal stem cells and cardiosphere-derived cells is in Phase 2–3 testing.

Device-based therapies include cardiac contractility modulation (CCM), baroreflex activation therapy, and interatrial shunt devices for HFpEF. These offer non-pharmacological options for patients who remain symptomatic despite optimal medical therapy.

Patient considerations: Heart failure trials stratify by ejection fraction (HFrEF vs HFpEF vs HFmrEF), so know your most recent echocardiogram results. Expect regular NT-proBNP blood tests, 6-minute walk tests, and quality-of-life questionnaires. Many trials require stable heart failure medications for 4+ weeks before enrollment and exclude patients with recent hospitalization within 30 days.